Summit Therapeutics Inc. Quarterly Nonoperating Income (Expense) in USD from Q1 2020 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Summit Therapeutics Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2020 to Q2 2025.
  • Summit Therapeutics Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2025 was $2.73M, a 16.9% increase year-over-year.
  • Summit Therapeutics Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2025 was $15.7M, a 20.5% decline year-over-year.
  • Summit Therapeutics Inc. annual Nonoperating Income (Expense) for 2024 was $13.4M, a 19.5% increase from 2023.
  • Summit Therapeutics Inc. annual Nonoperating Income (Expense) for 2023 was $11.2M.
  • Summit Therapeutics Inc. annual Nonoperating Income (Expense) for 2022 was -$2.29M, a 5.13% increase from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2025 $15.7M $2.73M +$395K +16.9% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-11
Q1 2025 $15.3M $3.94M +$1.9M +93.3% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-01
Q4 2024 $13.4M $6.87M -$9.23M -57.3% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-24
Q3 2024 $22.6M $2.12M +$2.9M Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-30
Q2 2024 $19.7M $2.33M +$1.26M +117% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-11
Q1 2024 $18.4M $2.04M +$7.26M Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-01
Q4 2023 $11.2M $16.1M +$10.6M +194% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-24
Q3 2023 $550K -$776K +$3.67M +82.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-30
Q2 2023 -$3.12M $1.08M +$5.16M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$8.28M -$5.22M -$5.98M -786% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-01
Q4 2022 -$2.29M $5.47M +$6.52M Oct 1, 2022 Dec 31, 2022 10-K 2025-02-24
Q3 2022 -$8.82M -$4.45M -$4.33M -3834% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$4.48M -$4.08M -$3.39M -495% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 -$1.09M $761K +$1.33M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$2.42M -$1.05M +$954K +47.6% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 -$3.37M -$113K +$745K +86.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$4.12M -$686K -$572K -502% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$3.54M -$565K -$3.83M -117% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-11
Q4 2020 $283K -$2.01M Oct 1, 2020 Dec 31, 2020 10-K/A 2022-12-21
Q3 2020 -$858K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$114K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $3.26M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.